CalciMedica Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica Inc. (NASDAQ:CALC) was the recipient of a large increase in short interest in the month of August. As of August 31st, there was short interest totaling 63,200 shares, an increase of 77.5% from the August 15th total of 35,600 shares. Based on an average daily volume of 73,900 shares, the short-interest ratio is currently 0.9 days. Approximately 1.1% of the shares of the company are short sold. Approximately 1.1% of the shares of the company are short sold. Based on an average daily volume of 73,900 shares, the short-interest ratio is currently 0.9 days.

Insiders Place Their Bets

In related news, insider Eric W. Roberts purchased 9,200 shares of CalciMedica stock in a transaction on Thursday, August 28th. The stock was purchased at an average cost of $2.86 per share, with a total value of $26,312.00. Following the acquisition, the insider directly owned 70,107 shares in the company, valued at approximately $200,506.02. This trade represents a 15.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Sudarshan Hebbar purchased 9,563 shares of CalciMedica stock in a transaction on Tuesday, August 19th. The stock was bought at an average cost of $2.82 per share, with a total value of $26,967.66. Following the completion of the acquisition, the insider owned 61,539 shares in the company, valued at approximately $173,539.98. This trade represents a 18.40% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 70,966 shares of company stock valued at $184,320. Insiders own 41.55% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of CALC. Cetera Investment Advisers boosted its stake in CalciMedica by 37.1% during the 4th quarter. Cetera Investment Advisers now owns 16,873 shares of the company’s stock worth $60,000 after acquiring an additional 4,566 shares during the last quarter. Atria Investments Inc raised its holdings in shares of CalciMedica by 20.0% in the second quarter. Atria Investments Inc now owns 44,700 shares of the company’s stock valued at $72,000 after purchasing an additional 7,436 shares during the last quarter. First Manhattan CO. LLC. acquired a new stake in shares of CalciMedica in the first quarter valued at approximately $25,000. 180 Wealth Advisors LLC acquired a new stake in shares of CalciMedica in the first quarter valued at approximately $31,000. Finally, Millennium Management LLC raised its holdings in shares of CalciMedica by 30.5% in the fourth quarter. Millennium Management LLC now owns 72,057 shares of the company’s stock valued at $255,000 after purchasing an additional 16,824 shares during the last quarter.

CalciMedica Trading Down 7.6%

Shares of CALC stock opened at $3.17 on Friday. CalciMedica has a 52-week low of $1.42 and a 52-week high of $5.65. The stock has a market cap of $44.29 million, a price-to-earnings ratio of -1.98 and a beta of 1.32. The company has a debt-to-equity ratio of 1.39, a quick ratio of 5.45 and a current ratio of 5.45. The firm has a fifty day moving average of $2.90 and a 200-day moving average of $2.18.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.40). On average, equities research analysts forecast that CalciMedica will post -2.21 earnings per share for the current fiscal year.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.